Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

LX7101

Other · developed by Lexicon Pharmaceuticals

Phase 1/2 Most advanced trial (none active)

LXRX Developer

1 Registered trials

What is LX7101?

LX7101 is an investigational drug studied in Primary Open-angle Glaucoma, Ocular Hypertension.

At a glance

Drug type: Other
Therapy area: Ophthalmology
Developer: Lexicon Pharmaceuticals (LXRX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII: 74B3C4ZT96

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT01528111	Phase 1/2	Primary Open-angle Glaucoma	Completed	LXRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Ocular HypertensionPrimary Open-angle Glaucoma

More from Lexicon Pharmaceuticals

Sotagliflozin FDA approved LX9211 Phase 2 Octreotide LAR Depot Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the LXRX page.

Follow LXRX, the company behind LX7101

See LXRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LXRX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z